Treatment strategies to improve and sustain remission in major depressive disorder

Madhukar H. Trivedi, Ella J. Daly

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that even with systematic measurement-based treatment, approximately one third of patients reach full remission after one treatment trial, with only two thirds reaching remission after four treatment trials. Treatment-resistant depression (TRD) is therefore a common problem in the treatment of MDD, with 60% to 70% of all patients meeting the criteria for TRD. Given the huge burden of major depressive illness, the low rate of full recovery remains suboptimal. The following article reports on some current treatment strategies available to improve rates of, and to sustain, remission in MDD.

Original languageEnglish (US)
Pages (from-to)377-384
Number of pages8
JournalDialogues in Clinical Neuroscience
Issue number4
StatePublished - 2008


  • Function
  • Remission
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Treatment strategies to improve and sustain remission in major depressive disorder'. Together they form a unique fingerprint.

Cite this